Reclast Approved For Once Yearly Treatment Of Postmenopausal Osteoporosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Zoledronic acid is the only osteoporosis therapy proven to reduce fractures across all key sites, Novartis claims.
You may also be interested in...
Novartis’ Reclast Approved For Fracture Prevention
Expanded labeling for the once-yearly osteoporosis treatment follows the launch of DTC ads.
Novartis’ Reclast Approved For Fracture Prevention
Expanded labeling for the once-yearly osteoporosis treatment follows the launch of DTC ads.
Novartis’ Phase III Bone Drug Reclast Beats Actonel
Company seeks FDA clearance for treatment and prevention of steroid-induced osteoporosis.